Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007)

Peer-Reviewed Study · Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. · May 2007

Ghiringhelli F et al., 2007-05: Small clinical study showing that low-dose metronomic oral cyclophosphamide selectively reduced circulating regulatory T cells and restored T-cell and NK-cell function in advanced cancer patients.

oral administration of metronomic cyclophosphamide in advanced cancer patients induces a profound and selective reduction of circulating regulatory T cells

Abstract

Ghiringhelli F et al., 2007-05: Small clinical study showing that low-dose metronomic oral cyclophosphamide selectively reduced circulating regulatory T cells and restored T-cell and NK-cell function in advanced cancer patients. Comparator: within-patient before/after treatment (no placebo arm). Funder/COI not in the abstract; authors are INSERM Dijon, the group that also published the 5-FU/MDSC work. Dosing matters: this is METRONOMIC low-dose cyclophosphamide, not standard maximum-tolerated adjuvant CTX – the book's blanket claim that chemo raises Tregs is contradicted for this regimen and this schedule. Study type: uncontrolled series.